Ignacio PÃ©rez-Valero

List of Publications by Year
in descending order

72 papers	2,360 citations	236925 25 h-index	214800 47 g-index
77 all docs	77 docs citations	77 times ranked	3154 citing authors

#	Article	IF	Citations
1	Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2022, 40, 121-124.	0.5	2
2	Perception of HIV physicians in Spain towards diagnosis and management of neuropsychiatric comorbidities in people with HIV. HIV Medicine, 2022, 23, 969-977.	2.2	3
3	Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2022, 40, 121-124.	0.3	0
4	Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens. Open Forum Infectious Diseases, 2022, 9, .	0.9	8
5	Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 490-495.	2.1	6
6	Physiciansâ€™ opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. Journal of Antimicrobial Chemotherapy, 2020, 75, 466-472.	3.0	6
7	How well are we performing the initial assessment of HIVâ€positive patients? Results from a multicentre cohort in Spain. HIV Medicine, 2020, 21, 128-134.	2.2	0
8	Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016. Open Forum Infectious Diseases, 2020, 7, ofaa482.	0.9	2
9	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Research, 2019, 170, 104543.	4.1	32
10	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. Aids, 2019, 33, 475-481.	2.2	44
11	Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clinical Infectious Diseases, 2018, 67, 770-777.	5.8	29
12	Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study. AIDS Patient Care and STDs, 2018, 32, 112-118.	2.5	84
13	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV,the, 2018, 5, e23-e34.	4.7	83
14	Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 2444-2451.	3.0	6
15	Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIVâ€“Infected Adults. Journal of Infectious Diseases, 2018, 218, 1531-1540.	4.0	22
16	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV,the, 2017, 4, e205-e213.	4.7	43
17	Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 102-109.	2.1	19
18	Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. Aids, 2017, 31, 1253-1260.	2.2	30

#	Article	IF	Citations
19	Vocal emotion processing deficits in HIV-infected individuals. Journal of NeuroVirology, 2017, 23, 304-312.	2.1	2
20	Brief Report: Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 91-94.	2.1	7
21	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clinical Infectious Diseases, 2017, 65, 2112-2118.	5.8	88
22	Facial Emotion Processing in Aviremic HIV-infected Adults. Archives of Clinical Neuropsychology, 2016, 31, 401-410.	0.5	4
23	Switching regimens in virologically suppressed <scp>HIV</scp>â€1â€infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)â€containing regimens. HIV Medicine, 2016, 17, 3-16.	2.2	29
24	Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid. Open Forum Infectious Diseases, 2016, 3, ofw041.	0.9	1
25	Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 29-32.	0.5	0
26	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infectious Diseases, 2016, 3, ofw059.	0.9	34
27	Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients. Aids, 2016, 30, 75-82.	2.2	16
28	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1â€"Infected Patients Treated With Combined Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 21-29.	2.1	23
29	Second-line antiretroviral therapy and the human factor. Lancet HIV,the, 2015, 2, e34-e35.	4.7	0
30	Boosted Lopinavirâ€" Versus Boosted Atazanavirâ€"Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	5.8	6
31	Dual treatment with atazanavirâ€"ritonavir plus lamivudine versus triple treatment with atazanavirâ€"ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 775-784.	9.1	122
32	Dual treatment with lopinavirâ€"ritonavir plus lamivudine versus triple treatment with lopinavirâ€"ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 785-792.	9.1	131
33	RezolstaÂ® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat. AIDS Reviews, 2015, 17, 114-20.	1.0	7
34	Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations. PLoS ONE, 2014, 9, e90710.	2.5	17
35	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004â€"2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. PLoS ONE, 2014, 9, e116226.	2.5	19
36	CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study. Journal of the International AIDS Society, 2014, 17, 19656.	3.0	4

#	Article	IF	Citations
37	Facial emotional processing deficits in long-term HIV-suppressed patients. Journal of the International AIDS Society, 2014, 17, 19664.	3.0	3
38	Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy. Journal of the International AIDS Society, 2014, 17, 19578.	3.0	7
39	Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation. Journal of the American Heart Association, 2014, 3, e000844.	3.7	184
40	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. International Journal of Tuberculosis and Lung Disease, 2014, 18, 700-708.	1.2	11
41	A Prospective Cohort Study of Neurocognitive Function in Aviremic HIV-Infected Patients Treated With 1 or 3 Antiretrovirals. Clinical Infectious Diseases, 2014, 59, 1627-1634.	5.8	19
42	Compliance with national guidelines for <scp>HIV</scp> treatment and its association with mortality and treatment outcome: a study in a <scp>S</scp>panish cohort. HIV Medicine, 2014, 15, 86-97.	2.2	12
43	A Comparative Study of Neurocognitively Impaired Patients Receiving Protease Inhibitor Monotherapy or Triple-Drug Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 419-423.	2.1	5
44	Risk of clinically significant depression in <scp>HIV</scp>â€infected patients: effect of antiretroviral drugs. HIV Medicine, 2014, 15, 213-223.	2.2	30
45	Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study. BMC Infectious Diseases, 2014, 14, 379.	2.9	11
46	Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study. Journal of NeuroVirology, 2014, 20, 362-370.	2.1	8
47	Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance. Aids, 2014, 28, 932-934.	2.2	2
48	Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapy. AIDS Reviews, 2014, 16, 101-8.	1.0	7
49	Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects, Coris 2008â€“2010. Antiviral Therapy, 2013, 18, 161-170.	1.0	14
50	All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997â€“2010. BMC Infectious Diseases, 2013, 13, 382.	2.9	18
51	Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?. Aids, 2013, 27, 141-144.	2.2	2
52	Inequalities in <scp>HIV</scp> disease management and progression in migrants from <scp>L</scp>atin <scp>A</scp>merica and subâ€<scp>S</scp>aharan <scp>A</scp>frica living in <scp>S</scp>pain. HIV Medicine, 2013, 14, 273-283.	2.2	39
53	Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy. PLoS ONE, 2013, 8, e69493.	2.5	22
54	Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care. Antiviral Therapy, 2012, 17, 1-8.	1.0	43

#	Article	IF	Citations
55	Definition of Advanced Age in HIV Infection: Looking for an Age Cut-Off. AIDS Research and Human Retroviruses, 2012, 28, 1000-1006.	1.1	56
56	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-NaÃ¯ve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. Journal of Clinical Microbiology, 2012, 50, 407-413.	3.9	41
57	Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. Aids, 2012, 26, 1829-1834.	2.2	27
58	Comments to Garvey et al.: â€œLow Rates of Neurocognitive Impairment Are Observed in Neuro-Asymptomatic HIV-Infected Subjects on Effective Antiretroviral Therapyâ€• HIV Clinical Trials, 2012, 13, 296-298.	2.0	0
59	Analysis of transmitted drug resistance in Spain in the years 2007â€“2010 documents a decline in mutations to the non-nucleoside drug class. Clinical Microbiology and Infection, 2012, 18, E485-E490.	6.0	26
60	Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care and Research, 2012, 64, n/a-n/a.	3.4	32
61	Mortality risk factors in patients with zygomycosis: a retrospective and multicentre study of 25 cases. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 263-268.	0.5	9
62	Protease inhibitor monotherapy. Current Opinion in Infectious Diseases, 2011, 24, 7-11.	3.1	31
63	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naÃ¯ve HIV-infected patients (CoRIS). Antiviral Research, 2011, 89, 19-25.	4.1	20
64	Protease inhibitor monotherapy and the CNS: peace of mind?. Journal of Antimicrobial Chemotherapy, 2011, 66, 1954-1962.	3.0	56
65	Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy. Aids, 2010, 24, 2415-2316.	2.2	0
66	Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. HIV Medicine, 2010, 11, 439-447.	2.2	15
67	Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. Journal of Viral Hepatitis, 2010, 17, 714-719.	2.0	23
68	Idiopathic intracranial hypertension and systemic lupus erythematosus: a case report and review of the literature. Lupus, 2009, 18, 1121-1123.	1.6	17
69	Ictus and antiphospholipid syndrome: How much is enough?. Autoimmunity, 2008, 41, 140-142.	2.6	4
70	Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Journal of Antimicrobial Chemotherapy, 2008, 61, 1359-1361.	3.0	52
71	Primary SjÃ¶gren Syndrome in Spain. Medicine (United States), 2008, 87, 210-219.	1.0	459
72	Letter to the Editor. Lupus, 2005, 14, 979-980.	1.6	7